avigena

OMNIINSIGHT™ PROSTATE CANCER PROGRAM

*A comprehensive, MENA-focused approach integrating **polygenic risk scores (PRS)**, **monogenic variant testing, clinical factors, and lifestyle** to deliver individualized prostate cancer prevention strategies.*



WHY PRS MATTERS

- Traditional genetic testing **alone is not enough.**
- PRS detects hidden high risk—**even in men with no mutations.**
- PRS modulates the penetrance of single-gene **mutations like BRCA,** meaning two patients with the same variant may have very different levels of risk.
- Uses a clinically validated multi-ancestry PRS, calibrated for diverse populations including the **MENA region.**

PERSONALIZED PREVENTION

Results are translated into **a clinically actionable care plan** aligned with best-practice guidelines, enabling personalized recommendations for **screening, lifestyle modification, medical interventions, and genetic counseling.**

avigena

MONOGENIC RISK COVERAGE

Monogenic Risk Coverage Identifies high-impact pathogenic variants across **NCCN**-recommended prostate cancer genes, including: **BRCA1, BRCA2, ATM, PALB2, CHEK2, HOXB13, MLH1, MSH2, MSH6, PMS2.**

POWERED BY BLENDED GENOME EXOME

The innovative genomic technology is developed in collaboration **with Broad Clinical Labs at Harvard and MIT**, the program combines **95.5× Whole- Exome Sequencing (WES)** with **genome-wide lcWGS** to detect both rare mutations and polygenic risk with high precision.

Testing is performed through **CAP/CLIA-accredited laboratories,** with analytics support from **Allelica**, (MGB/LMM), and regional collaboration with **Novo Genomics.**
Equipped with most precise risk assessment available.

SCAN ME

Get started today
info@avigena.com
+1 617 412 5580